|
🇺🇸 FDA Workshop - Nitrosamine-driven Reformulation and Bioequivelance
|
|
1
|
233
|
April 17, 2026
|
|
Toxycologist ... not for you!
|
|
2
|
237
|
April 17, 2026
|
|
Regarding the structural determination of N-nitrosyl abecacil
|
|
0
|
67
|
April 15, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
113
|
April 14, 2026
|
|
Testing of APIs for NDSRI
|
|
5
|
1294
|
April 12, 2026
|
|
FDA/CRCG Workshop on Bioequivalence Innovations for Generic Oral Products
|
|
0
|
107
|
April 11, 2026
|
|
AMES Test Study Designs for Nitrosamine Mutagenicity Testing -Pub
|
|
13
|
1600
|
April 9, 2026
|
|
Excipient Selection Strategies to Mitigate Nitrosamine Risks
|
|
0
|
202
|
April 8, 2026
|
|
Would EDTA disodium form nitrosamines?
|
|
13
|
4485
|
April 8, 2026
|
|
N-Nitroso meglumine
|
|
26
|
2267
|
April 8, 2026
|
|
N-Nitrosamine Risk Management: From Toxicology to Targeted Analysis-Webinar
|
|
1
|
309
|
April 7, 2026
|
|
Society of Toxicology STO 2026 -Posters
|
|
1
|
111
|
April 7, 2026
|
|
Everthing you wanted to know about In vivo COMET assay -webinar
|
|
0
|
93
|
April 3, 2026
|
|
MDD for cream formulation
|
|
0
|
100
|
April 3, 2026
|
|
All are welcomed to participate in the Stakeholder Survey concerning a Potential USP Public Standard on Mutagenic Impurities
|
|
0
|
114
|
April 2, 2026
|
|
Question on the Method for Determining the Maximum Allowable Daily Usage of Terbinafine Ointment and Solution Formulations
|
|
2
|
159
|
April 2, 2026
|
|
🇸🇬 Singapore formalized Nitrosamine requirements for NDA and GDA Applications
|
|
0
|
130
|
April 1, 2026
|
|
FDA Announcement - Small Molecule Nitrosamines in Infusion Bags
|
|
17
|
2836
|
March 31, 2026
|
|
N-nitroso-Furosemide
|
|
2
|
520
|
March 31, 2026
|
|
Analysis method of cream
|
|
6
|
274
|
March 30, 2026
|
|
Determination of N-nitroso Caspofungin
|
|
1
|
115
|
March 27, 2026
|
|
Excipient Nitrosamine Risk Assessment Tool
|
|
1
|
518
|
March 26, 2026
|
|
Nitrosamine formation in differnt dosage forms
|
|
10
|
412
|
March 24, 2026
|
|
Optimized UHPLC–Derivatization Method for Low-Level Nitrite Detection in Pharmaceutical Excipients-Pub
|
|
0
|
212
|
March 23, 2026
|
|
Impact of post approval quantitative changes in excipient composition on nitrosamine formation: De-risking strategy-Pub
|
|
0
|
134
|
March 23, 2026
|
|
👨💻 Determination of nitrite and nitrate in Microcrystalline Cellulose by ion chromatography
|
|
0
|
224
|
March 23, 2026
|
|
How to Validate High-Resolution Mass Spectrometry for Nitrosamine Detection in Pharmaceuticals
|
|
3
|
365
|
March 21, 2026
|
|
N-Nitrosoatorvastatin and applicable potency category 4 or 5
|
|
2
|
125
|
March 20, 2026
|
|
Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids-Pub
|
|
0
|
75
|
March 20, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
322
|
March 19, 2026
|